Evidence map›Paper›PMID 39187586›Full record

ArticleScientific reports2024

PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab.

Takashi Matsuki, Daisuke Kawakita, Hideaki Takahashi, Takuro Okada, Akihiro Sakai, Yushi Ueki, Hiroshi Tsuge, Kenji Hanyu, Kaho Momiyama, Ryusuke Shodo and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takashi MatsukiDepartment of Head and Neck Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan.
Daisuke KawakitaDepartment of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, 467‑8602, Japan.
Hideaki TakahashiDepartment of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Kanagawa, 236‑0004, Japan.
Takuro OkadaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University School of Medicine, Tokyo, 160‑0023, Japan.
Akihiro SakaiDepartment of Otolaryngology-Head and Neck Surgery, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Yushi UekiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951‑8520, Japan.
Hiroshi TsugeDepartment of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, 467‑8602, Japan.
Kenji HanyuDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University School of Medicine, Tokyo, 160‑0023, Japan.
Kaho MomiyamaDepartment of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, 252‑0375, Japan.
Ryusuke ShodoDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951‑8520, Japan.
Mayu YamauchiDepartment of Otolaryngology-Head and Neck Surgery, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Yukiko AsakoDepartment of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, 252‑0375, Japan.
Hideaki HiraiDepartment of Anatomic Pathology, Tokyo Medical University School of Medicine, Tokyo, 160‑0023, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University School of Medicine, Tokyo, 160‑0023, Japan.
Yuichiro TadaDepartment of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, 1-4-3 Mita, Minato-Ku, Tokyo, 108-8329, Japan. ytada@iuhw.ac.jp.

Funding

Japan Society for the Promotion of Science 19K09873Japan Society for the Promotion of Science 20K07597Japan Society for the Promotion of Science 20K10508Japan Society for the Promotion of Science 21K09616Japan Society for the Promotion of Science 22K06969Japan Society for the Promotion of Science 23K06432
6 · The paper itself

Abstract

Although immune checkpoint inhibitors (ICIs) are effective in some patients with salivary gland carcinoma (SGC), biomarkers which predict the efficacy and prognosis of SGC patients treated with pembrolizumab have not been identified. We conducted a multi-institutional retrospective cohort study to evaluate the efficacy and safety of pembrolizumab monotherapy in patients with recurrent and/or metastatic SGC and to determine optimal cut-off values of the combined positive score (CPS) and tumor proportion score (TPS) as numerical expression levels of programmed death-ligand 1 (PD-L1), which predict the efficacy of pembrolizumab. Furthermore, we investigated the association of patient characteristics and hematological markers with clinical outcomes, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). From 2016 to 2021, 27 patients were included in the analysis. ORR of SGC was 25.9%. Optimal cut-off values of CPS and TPS were 15 and 25%, respectively. ORRs of CPS-high and TPS-high were 55.6 and 75.0%, respectively, and significantly higher than those of CPS-low and TPS-low. Furthermore, patients with a low platelet-lymphocyte ratio (PLR) had a significantly longer PFS. No grade 4 or greater adverse events were observed. This study demonstrated the efficacy and safety of pembrolizumab monotherapy and identified optimal cut-off values of CPS and TPS.

Indexed as

Antibodies, Monoclonal, HumanizedB7-H1 AntigenBiomarkers, TumorSalivary Gland NeoplasmsAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalPrognosisProgression-Free SurvivalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD274 protein, humanpembrolizumabCombined positive scoreImmune checkpoint inhibitorsPembrolizumabProgrammed death-ligand 1Salivary gland carcinomaTumor proportion score

Identifiers

PMID39187586
PMCPMC11347672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.